BrainEver has joined in a long-term partnership with 3P Biopharmaceuticals to advance in development its lab-made form of the human protein Engrailed 1 (EN1) as a potential treatment of amyotrophic lateral sclerosis (ALS) and like conditions. Under the terms of the collaboration, 3P will be in charge of…
BrainEver, 3P Partner to Move ALS Therapy Into Clinical Trials
I’ll admit that because I live with ALS, some of my past “Human vs. Automation” experiences have been, um, less than perfect. Touchpads that open automated doors don’t always work for me, and voice activation software doesn’t recognize my commands. But now, I have a new sense of…
The European Medicines Agency (EMA) has agreed to review an application seeking the approval of tofersen in treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, the therapy’s developer, Biogen, reported. “Today’s announcement is an important milestone for the ALS community in Europe where there is a tremendous need…
EpicentRx has been awarded funding from FightMND to study how well RRx-001, its lead small molecule, may protect nerve cells against damage caused by amyotrophic lateral sclerosis (ALS), a disease also known as motor neuron disease (MND). “We are very pleased to receive this support from FightMND…
Researchers have developed a brain-machine interface (BMI) that could someday facilitate communication for people who have lost their ability to speak, including those with amyotrophic lateral sclerosis (ALS). After being trained to recognize certain patterns of nerve cell activity, the BMI could accurately predict the words a person with…
Family fun has gotten harder to come by since my husband, Todd, was diagnosed with ALS and the disease has progressed. Initially, Todd could still walk, but his legs tired easily, so we needed to pace ourselves. It got increasingly difficult to go out as his muscles weakened, but…
A soft robotic implantable device that can exert mechanical force on muscles was shown to reduce muscle atrophy in a mouse model in a recent study. Based on the findings, researchers believe the device may be able to be applied in diseases such as amyotrophic lateral sclerosis (ALS) that…
Veterans with amyotrophic lateral sclerosis (ALS) are calling for the U.S. Food and Drug Administration (FDA) to hold a public advisory committee meeting to discuss the benefits of NurOwn — an investigational cell-based therapy that military service members say has slowed their disease. The request follows the regulatory…
I’m excited to share good news about the growing access by ALS patients to the benefits of mindfulness and meditation. As readers of this column likely know, I’ve been on a quest to increase awareness in the ALS community about these wonderful mind-body practices. Being mindful…
Note: This story was updated Nov. 30, 2022, to indicate six patients in the Phase 2a part of FOCUS-C9 will receive a monthly 10 mg dose of WVE-004 over four months. An ongoing clinical trial of Wave Life Sciences’ WVE-004 in people with amyotrophic lateral sclerosis (ALS) and…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.